{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:59:41Z","timestamp":1780621181431,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-026-02101-1","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T03:04:00Z","timestamp":1776913440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dynamic changes in homologous recombination status before and after chemotherapy in advanced ovarian, fallopian tube, and primary peritoneal cancers"],"prefix":"10.1186","volume":"19","author":[{"given":"Akemi","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Teramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakiko","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoka","family":"Usami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"2101_CR1","unstructured":"World Cancer Research Fund. Cancer statistics: Ovarian cancer statistics. https:\/\/www.wcrf.org\/cancer-trends\/ovarian-cancer-statistics\/. Accessed o1 Aug 2025."},{"key":"2101_CR2","first-page":"284","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284\u201396.","journal-title":"CA Cancer J Clin"},{"key":"2101_CR3","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:833\u201348.","journal-title":"Ann Oncol"},{"key":"2101_CR4","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1111\/cas.15477","volume":"113","author":"H Onji","year":"2022","unstructured":"Onji H, Murai J. Reconsidering the mechanisms of action of PARP inhibitors based on clinical. Cancer Sci. 2022;113:2943\u201351.","journal-title":"Cancer Sci"},{"key":"2101_CR5","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez-Mart\u00edn A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416\u201328.","journal-title":"N Engl J Med"},{"key":"2101_CR6","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495\u2013505.","journal-title":"N Engl J Med"},{"key":"2101_CR7","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391\u2013402.","journal-title":"N Engl J Med"},{"key":"2101_CR8","unstructured":"Myriad Genetics, MyChoice companion Diagnoitic test. 2025. https:\/\/myriad.com\/genetic-tests\/mychoicecdx-tumor-test\/. Accessed 01 Aug 2025."},{"key":"2101_CR9","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22:3764\u201373.","journal-title":"Clin Cancer Res"},{"key":"2101_CR10","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/s41416-018-0268-6","volume":"119","author":"JN Patel","year":"2018","unstructured":"Patel JN, Braicu I, Timms KM, Solimeno C, Tshiaba P, Reid J, et al. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer. Br J Cancer. 2018;119:1060\u20136.","journal-title":"Br J Cancer"},{"key":"2101_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ygyno.2014.04.013","volume":"133","author":"DG Mutch","year":"2014","unstructured":"Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 2014;133:401\u20134.","journal-title":"Gynecol Oncol"},{"key":"2101_CR12","doi-asserted-by":"publisher","first-page":"100445","DOI":"10.1016\/j.modpat.2024.100445","volume":"37","author":"M Romey","year":"2024","unstructured":"Romey M, Rodepeter F, Hattesohl A, Kaiser K, Teply-Szymanski J, Heitz F, et al. Systematic analysis of homologous recombination deficiency testing in ovarian cancer\u2014development of recommendations for optimal assay performance. Mod Pathol. 2024;37:100445.","journal-title":"Mod Pathol"},{"key":"2101_CR13","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1136\/ijgc-2019-000989","volume":"30","author":"YL Liu","year":"2020","unstructured":"Liu YL, Zhou QC, Iasonos A, Filippova OT, Chi DS, Zivanovic O, et al. Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer. Int J Gynecol Cancer. 2020;30:1554\u201361.","journal-title":"Int J Gynecol Cancer"},{"key":"2101_CR14","doi-asserted-by":"publisher","first-page":"1372482","DOI":"10.3389\/fonc.2024.1372482","volume":"14","author":"Y Xu","year":"2024","unstructured":"Xu Y, Chen YA, Wu Y, Saverimuthu A, Jadhav A, Bhuiyan R, et al. The prognostic and predictive value of homologous recombination deficiency status in patients with advanced stage epithelial ovarian carcinoma after first-line platinum-based chemotherapy. Front Oncol. 2024;14:1372482.","journal-title":"Front Oncol"},{"key":"2101_CR15","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonz\u00e1lez-Mart\u00edn A, Marth C. PAOLA-1\/ENGOT-ov25 investigators. Ann Oncol. 2023;34:681\u201392.","journal-title":"Ann Oncol"},{"key":"2101_CR16","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","volume":"33","author":"S B\u00f6hm","year":"2015","unstructured":"B\u00f6hm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, et al. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol. 2015;33:2457\u201363.","journal-title":"J Clin Oncol"},{"key":"2101_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ygyno.2019.11.013","volume":"156","author":"H Takaya","year":"2020","unstructured":"Takaya H, Nakai H, Sakai K, Nishio K, Murakami K, Mandai M, et al. Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course. Gynecol Oncol. 2020;156:415\u201322.","journal-title":"Gynecol Oncol"},{"key":"2101_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40364-015-0033-4","volume":"3","author":"AM Marquard","year":"2015","unstructured":"Marquard AM, Eklund AC, Joshi T, Krzystanek M, Favero F, Wang ZC, et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res. 2015;3:9.","journal-title":"Biomark Res"},{"key":"2101_CR19","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1158\/1078-0432.CCR-24-1225","volume":"30","author":"DL Richardson","year":"2024","unstructured":"Richardson DL, Quintanilha JCF, Danziger N, Li G, Sokol E, Schrock AB, et al. Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1\/2 and a scar-based HRD signature in real-world practice. Clin Cancer Res. 2024;30:4644\u201353.","journal-title":"Clin Cancer Res"},{"key":"2101_CR20","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40291-024-00726-w","volume":"28","author":"Y Liu","year":"2024","unstructured":"Liu Y, Chen X, Lu H, Wu X, Liu X, Xu F, et al. Is the homologous recombination repair mutation defined by a 15-gene panel associated with the prognosis of epithelial ovarian cancer? Mol Diagn Ther. 2024;28:621\u201332.","journal-title":"Mol Diagn Ther"},{"key":"2101_CR21","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/jnci\/djaa193","volume":"113","author":"C Callens","year":"2021","unstructured":"Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillerm E, et al. Concordance between tumor and germline BRCA status in high-grade ovarian carcinoma patients in the phase III PAOLA-1\/ENGOT-ov25. J Natl Cancer Inst. 2021;113:917\u201323.","journal-title":"J Natl Cancer Inst"},{"key":"2101_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/cas.15518","volume":"114","author":"K Oda","year":"2023","unstructured":"Oda K, Aoki D, Tsuda H, Nishihara H, Aoyama H, Inomata H, et al. Cancer Sci. 2023;114:271\u201380.","journal-title":"Cancer Sci"},{"key":"2101_CR23","doi-asserted-by":"publisher","first-page":"1435029","DOI":"10.3389\/fonc.2024.1435029","volume":"14","author":"Q Zhao","year":"2024","unstructured":"Zhao Q, Bai L, Tan Y, Qie M. Limitations of homologous recombination status testing and poly (ADP-ribose) polymerase inhibitor treatment in the current management of ovarian cancer. Front Oncol. 2024;14:1435029.","journal-title":"Front Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-02101-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02101-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02101-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:18Z","timestamp":1780617618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-02101-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2101"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-02101-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7947639\/v1","asserted-by":"object"}]},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"25 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Institutional Review Board of Ehime University Hospital (approval number 2212007). Written informed consent was obtained from participants who were under active follow-up when additional testing of archived tumor tissue was required. For the remaining patients, an opt-out consent process was applied, and study information was disclosed on the hospital\u2019s official website in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects in Japan. The study was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"204"}}